Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28249239 | 1.00 | ATM (0.42) | ATMBCHEPARP1CHRM3SMN1; SMN2 | |
| SCHEMBL3696868 | 0.90 | BCHE (0.48) | BCHEPARP1SMN1; SMN2KDM2BCYP2D6 | |
| SCHEMBL3687879 | 0.90 | BCHE (0.48) | BCHEPARP1SMN1; SMN2KDM2BCYP2D6 | |
| SCHEMBL26088863 | 0.86 | SMN1; SMN2 (0.50) | ATMBCHECHRM3SMN1; SMN2CYP2D6 | |
| SCHEMBL28249223 | 0.84 | ATM (0.40) | ATMPARP1CHRM3SMN1; SMN2CYP2D6 | |
| SCHEMBL6961255 | 0.84 | ATM (0.40) | ATMPARP1CHRM3SMN1; SMN2CYP2D6 | |
| SCHEMBL28972352 | 0.81 | CHRM2 (0.40) | ATMBCHECHRM3 | |
| SCHEMBL29103884 | 0.81 | CHRM2 (0.40) | ATMBCHECHRM3 | |
| SCHEMBL27762899 | 0.80 | CHRM3 (0.49) | BCHECHRM3 | |
| SCHEMBL27675066 | 0.79 | SMN1; SMN2 (0.58) | ATMBCHECHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | ATM 373/4885BCHE 3782/4885PARP1 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.